| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $2.7M | — | +8.1% |
| SG&A Expense | $1.7M | — | +22.3% |
| Operating Income | -$4.5M | — | -13.2% |
| Net Income | -$4.5M | — | -12.5% |
| EPS (Basic) | -$0.64 | — | -146.2% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $18.0M | +130.5% | +420.4% |
| Current Assets | $18.8M | +125.0% | +351.6% |
| Total Assets | $20.3M | +99.9% | +237.9% |
| Current Liabilities | $3.4M | +54.2% | +56.6% |
| Total Liabilities | $3.4M | +53.7% | — |
| Stockholders' Equity | $16.9M | +112.6% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$3.1M | — | +24.6% |
| Financing Cash Flow | $13.4M | — | +121.6% |
| +337.7% |